We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Fully Automated Analyzer Has Multiplex Capabilities

By LabMedica International staff writers
Posted on 16 Aug 2010
A state of the art analyzer offers complete consolidation of the patient's profile for clinical diagnostics. More...


The new advanced machine uses Biochip Array Technology and is capable of testing for multiple analytes simultaneously from a single sample, providing advanced test compilation, and patient profiling.

The Evidence Evolution analyzer provides limitless capabilities enabling simultaneous testing from a single small volume sample. A complete profile of biomarkers can be analyzed from as little as 7.0 µL of sample and the assay menu is extensive. The Evidence Evolution has the ability to process 2,940 tests per hour.

The analyzer was unveiled by Randox Laboratories Ltd. (Crumlin, UK), at the American Association Clinical Chemistry's Clinical Lab Expo in Anaheim (CA, USA) in July 2010. Multiplex testing allows multiple tests to be carried out from an undivided patient sample reducing the amount of time and labor spent on individual tests. True Random Access allows continuous reagents samples and consumable input and output without interrupting testing and batch samples are processed with instant STAT capabilities. The highly accurate testing is achieved by the use of linear Bio-drive Robotics, which delivers fast and highly precise operations with uncompromised quality. The unrivalled mechanical capabilities ensure continuous flow of results.

The array menus include clinical, immunoassays, molecular diagnostics, toxicology, and drug residue assays. The Evidence Evolution is suitable for clinical laboratories with medium to high throughput. The measurement principle is based on chemiluminescence with a 200-biochip capacity yielding up to 9,800 tests containing up to 20 different panels onboard simultaneously. The system also hosts high quality and highly secure remote access diagnostics, ensuring advanced technical support is never more than a click away.

Related Links:

Randox Laboratories Ltd.
American Association Clinical Chemistry




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Automated Immunoassay Analyzer
SuperFlex™
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.